Pmv Pharmaceuticals IncPMVP
± MixedCapitalrelevance
PMV Pharmaceuticals priced a $50.8M oversubscribed public offering of shares and warrants, a financing event for the company.
Impact on stocks 1
Biotech & Genomic Medicine
Pmv Pharmaceuticals IncPMV Pharmaceuticals has priced its oversubscribed public offering, expected to raise about $50.8 million in gross proceeds. The offering includes 22.055 million shares of common stock and pre-funded warrants to purchase up to 19.9 million shares, along with warrants to purchase an aggregate of 41.955 million shares of common stock. The combined offering price is $1.21 per share and accompanying warrant, with pre-funded warrants priced at $1.20999 each and an exercise price of $0.00001 per share. PMV Pharma, a precision oncology company developing small-molecule therapies targeting p53, notes that TP53 mutations are found in approximately half of all cancers. The offering is expected to close on or about September 2.
Pmv Pharmaceuticals IncPMV Pharmaceuticals priced a $50.8M oversubscribed public offering of shares and warrants, a financing event for the company.